Ardelyx, Inc, a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-745-1700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.61 million
Profitability
Miscellaneous
Employees86
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Ardelyx (NASDAQ:ARDX) Frequently Asked Questions
What is Ardelyx's stock symbol?
Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."
How were Ardelyx's earnings last quarter?
Ardelyx Inc (NASDAQ:ARDX) released its quarterly earnings data on Friday, August, 9th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.02. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.60 million. View Ardelyx's Earnings History.
When is Ardelyx's next earnings date?
What price target have analysts set for ARDX?
1 brokerages have issued 1-year target prices for Ardelyx's stock. Their forecasts range from $15.00 to $15.00. On average, they expect Ardelyx's stock price to reach $15.00 in the next year. This suggests a possible upside of 190.1% from the stock's current price. View Analyst Price Targets for Ardelyx.
What is the consensus analysts' recommendation for Ardelyx?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ardelyx.
Has Ardelyx been receiving favorable news coverage?
News coverage about ARDX stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Ardelyx earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Ardelyx.
Are investors shorting Ardelyx?
Ardelyx saw a drop in short interest during the month of August. As of August 31st, there was short interest totalling 389,800 shares, a drop of 6.0% from the July 31st total of 414,600 shares. Based on an average daily volume of 187,500 shares, the days-to-cover ratio is presently 2.1 days. Currently, 0.8% of the company's stock are sold short. View Ardelyx's Current Options Chain.
Who are some of Ardelyx's key competitors?
Some companies that are related to Ardelyx include Opko Health (OPK), Theravance Biopharma (TBPH), Ra Pharmaceuticals (RARX), BELLUS Health (BLUSF), AnaptysBio (ANAB), Innoviva (INVA), Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Epizyme (EPZM), Spectrum Pharmaceuticals (SPPI), Zymeworks (ZYME), Amphastar Pharmaceuticals (AMPH), Esperion Therapeutics (ESPR), Axsome Therapeutics (AXSM) and Dicerna Pharmaceuticals (DRNA).
What other stocks do shareholders of Ardelyx own?
Who are Ardelyx's key executives?
Ardelyx's management team includes the folowing people:
- Mr. Michael G. Raab, Pres, CEO & Director (Age 54)
- Mr. David Rosenbaum, Chief Devel. Officer (Age 58)
- Mr. Mark E. Kaufmann, CFO & Treasurer (Age 51)
- Mr. Jeffrey W. Jacobs, Sr. VP of Technical Operations (Age 56)
- Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 65)
Who are Ardelyx's major shareholders?
Ardelyx's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.79%), Pekin Hardy Strauss Inc. (3.78%), Renaissance Technologies LLC (3.35%), Vanguard Group Inc. (2.80%), D. E. Shaw & Co. Inc. (1.29%) and Northern Trust Corp (0.85%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Gordon Ringold, Mark Kaufmann, Michael Raab, Reginald Seeto and Scott D Sandell. View Institutional Ownership Trends for Ardelyx.
Which institutional investors are selling Ardelyx stock?
ARDX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Pekin Hardy Strauss Inc., Man Group plc, Charles Schwab Investment Management Inc., Jacobs Levy Equity Management Inc., Wells Fargo & Company MN, Algert Global LLC and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann, Michael Raab and Scott D Sandell. View Insider Buying and Selling for Ardelyx.
Which institutional investors are buying Ardelyx stock?
ARDX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, D. E. Shaw & Co. Inc., Bank of America Corp DE, SG Americas Securities LLC, Bank of New York Mellon Corp, Northern Trust Corp and Citadel Advisors LLC. View Insider Buying and Selling for Ardelyx.
How do I buy shares of Ardelyx?
Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ardelyx's stock price today?
One share of ARDX stock can currently be purchased for approximately $5.17.
How big of a company is Ardelyx?
Ardelyx has a market capitalization of $324.68 million and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-91,300,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Ardelyx employs 86 workers across the globe.View Additional Information About Ardelyx.
What is Ardelyx's official website?
How can I contact Ardelyx?
Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]
MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
